APPROACH TO DIAGNOSIS AND TREATMENT STRATEGIES FOR PATIENT WITH TREATMENT RESISTANT DEPRESSION
Main Article Content
Abstract
Treatment resistant depression is a major depressive disorder that does not respond to conventional therapy. Authors have different perspectives on treatment resistant depression, but fundamentally, treatment resistant depression does not fully respond to at least two antidepressants. Treatment therapies include changing and combining antidepressants, chemotherapy enhancement such as lithium salt, triiodothyronine, new generation antipsychotics. There are also brain stimulant therapies that include electroconvulsive therapy, repetitive transcranial magnetic stimulation, deep brain stimulation, Vegus stimulation and magnetic seizure therapy. Therapies with little data mentioned include the using of ketamine, psilocybin, and anti-inflammatories, corticoid, etc. In this article, we would like to give an overview as well as a correct diagnostic and effective strategies for treatment resistant depression.
Keywords
major depressive disorder, treatment resistant depression, chemotherapy, electroconvulsive therapy, , repetitive transcranial magnetic stimulation, deep brain stimulation
Article Details
References
Sadock B. J., Sadock V. A., Ruiz P. et al (2015), “Mood disorder”, Kaplan and Sadock’s Synopsis of psychiatry, eleventh edition, Williams and Wilkins, 331-361.
Taylor D. M., Barnes T. R. E., Young A. H. et al, (2018), “The Mausley Prescribing Guidelines in Psychiatry thirteenth edition” Wiley Blackwell, 267- 277
Rush A. J., Trivedi M. H., Wisniewski S. R., et al. (2006), “Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report”, Am J Psychiatry, 163(11):1905–1917
Voineskos D., Daskalakis Z. J., Blumberger D.M. (2020), “Management of Treatment-Resistant Depression: Challenges and Strategies”, Neuropsychiatr Dis Treat, 16: 221–234.
Thase M. E., Rush A. J., Howland R. H., et al. (2002), “Double-blind switch study of imipramine or sertraline treatment of antidepressant-resistant chronic depression”. Arch Gen Psychiatry, 59(3):233–239.
Shelton R. C., Tollefson G. D., Tohen M., et al (2001), “A novel augmentation strategy for treating resistant major depression”, Am J Psychiatry, 158(1):131–134.
El-Khalili N., Joyce M., Atkinson .S, et al (2010), Extended-release quetiapine fumarate (quetiapine XR) as adjunctive therapy in major depressive disorder (MDD) in patients with an inadequate response to ongoing antidepressant treatment: a multicentre, randomized, double-blind, placebo-controlled study” Int J Neuropsychopharmacol, 13(7):917–932
Berlim M.T., Van den E. F., Tovar-Perdomo S., et al (2014), “Response, remission and drop-out rates following high-frequency repetitive transcranial magnetic stimulation (rTMS) for treating major depression: a systematic review and meta-analysis of randomized, double-blind and sham-controlled trials”, Psychol Med, 44(2):225––39
Carhart-Harris R. L., Bolstridge M., Rucker J., et al (2016), “Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study”, Lancet Psychiatry, 3(7):619–627.